Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Scott Kopetz, MD, PhD, on ANCHOR vs. BEACON: Identifying the Optimal Setting for Treatment

Posted: Monday, March 16, 2020

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, talks about the two trials; the rationale for exploring the triplet therapy encorafenib, binimetinib, and cetuximab in the first line in the ANCHOR study; and potential differences in the patient populations between ANCHOR and BEACON.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement